Transcript: Precigen Q1 2026 Earnings Conference Call

On Wednesday, Precigen (NASDAQ: PGEN ) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/ . The full earnings call is available at https://app.webinar.net/gM6Ljy5jKN3 Summary Precigen Inc reported strong financial performance with Q1 2026 net product revenue of $21.6 million from Papcemios, up from $3.4 million in Q4 2025. The company highlighted the successful commercial launch of Papcemios, supported by FDA approval, broad payer coverage, and strong adoption in both major medical centers and community practices. Management expressed optimism about continued growth, with plans to initiate a pediatric trial for Papcemios in Q4 2026 and updates on their PRGN 2009 immunotherapy program expected later in the year. The company reported an operating loss of $6 million for the quarter, with a net loss of $7.9 million, and ended the quarter with $56.7 million in cash and equivalents. Precigen Inc anticipates achieving cash flow breakeven by the end of 2026 without needing to access additional capital markets. Full Transcript OPERATOR Good afternoon ladies and gentlemen and welcome to the President's first quarter 2026 financial results and Business Updates Conference Call at this time all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Wednesday, May 13, 2026 and I would now like to turn the conference over to Mr. Steven Karasim. Please go ahead sir. Steven Karasim (Moderator) Thank you Operator and thank you for all those joining us today for our Q1 2026 update call. Joining me today are Dr. Helen Sabzavari, our President and CEO, Phil Tennant, our...